Fasting glucose
Decrease · moderate
Improves insulin sensitivity
Literature evidence
Compound library
Vivy evidence dossier
Semaglutide
Also indexed as Wegovy, Ozempic, Rybelsus
T1GLP-1
Read this entry as context, not instruction.
Evidence labels describe the material available in this reference entry. They do not establish that a compound is appropriate, effective, or safe for you. Inclusion is not a recommendation to use it.
Reference context
Pharmacokinetic context
Half-life7.0 days
This field summarizes the library record. Half-life can vary with formulation, indication, and individual clinical context.
Observed relationships
Biomarker context
HbA1c
Decrease · small
Improves glycemic control
Literature evidence
Fasting insulin
Decrease · moderate
Reduces insulin resistance
Literature evidence
HOMA-IR
Decrease · moderate
Improves insulin sensitivity
Literature evidence
Triglycerides
Decrease · small
Improves lipid metabolism
Literature evidence
HDL cholesterol
Increase · small
Improves lipid profile
Literature evidence
Keep in view
Safety discussion points
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and obesity. Common side effects include nausea, diarrhea, and constipation. Use with caution in patients with a history of pancreatitis.
Trace the entry
Sources
Keep the reference close
Track Semaglutide in context.
Hey Vivy helps you organize protocols and review change over time. It does not diagnose, prescribe, or replace qualified care.